Laropiprant: Difference between revisions
m Protected "Laropiprant": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
| Line 30: | Line 30: | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
| Line 38: | Line 38: | ||
In October 2008, Merck expanded the THRIVE Trial from 20,000 to 25,000 patients in order to expedite a second bid for FDA approval of its experimental cholesterol drug, MK-0524A. MK-0524A is a combination of [[niacin]] and laropiprant, which is aimed at limiting facial flushing associated with niacin. In April 2008 the FDA decided to withhold approval for the experimental drug, deciding to wait until the results of the THRIVE Trial could be analyzed.<ref>http://biz.yahoo.com/ap/081017/merck_cholesterol_study.html?.v=2</ref> | In October 2008, Merck expanded the THRIVE Trial from 20,000 to 25,000 patients in order to expedite a second bid for FDA approval of its experimental cholesterol drug, MK-0524A. MK-0524A is a combination of [[niacin]] and laropiprant, which is aimed at limiting facial flushing associated with niacin. In April 2008 the FDA decided to withhold approval for the experimental drug, deciding to wait until the results of the THRIVE Trial could be analyzed.<ref>http://biz.yahoo.com/ap/081017/merck_cholesterol_study.html?.v=2</ref> | ||
{{Lipid modifying agents}} | {{Lipid modifying agents}} | ||
Latest revision as of 16:47, 9 August 2012
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C21H19ClFNO4S |
| Molar mass | 435.90 g/mol |
|
WikiDoc Resources for Laropiprant |
|
Articles |
|---|
|
Most recent articles on Laropiprant Most cited articles on Laropiprant |
|
Media |
|
Powerpoint slides on Laropiprant |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Laropiprant at Clinical Trials.gov Clinical Trials on Laropiprant at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Laropiprant
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Laropiprant Discussion groups on Laropiprant Patient Handouts on Laropiprant Directions to Hospitals Treating Laropiprant Risk calculators and risk factors for Laropiprant
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Laropiprant |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Laropiprant (pINN; codenamed MK-0524A) is an investigational treatment for hypercholesterolemia. It is a prostanoid DP1 receptor antagonist. It will be marketed by Merck & Co. as a combination with niacin and will be sold under the tradenames Cordaptive and Tredaptive.
In October 2008, Merck expanded the THRIVE Trial from 20,000 to 25,000 patients in order to expedite a second bid for FDA approval of its experimental cholesterol drug, MK-0524A. MK-0524A is a combination of niacin and laropiprant, which is aimed at limiting facial flushing associated with niacin. In April 2008 the FDA decided to withhold approval for the experimental drug, deciding to wait until the results of the THRIVE Trial could be analyzed.[1]
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Hypolipidemic agents